The patent, which has terms that expire no earlier than 2031, covers the company’s unique formulation in conjunction with anti-obesity agents for the reduction of body weight in CVD patients and diabetics.
Pivotal Therapeutics chairman and chief scientific officer George Jackowski said this patent issuance represents an important step in further protecting and advancing the commercial potential of VASCAZEN’s formulation.
"Our unique 6:1 EPA:DHA formulation when used in combination with anti-obesity drugs may play a positive role in addressing Obesity," Jackowski said.
The issued patent is the first of seven patent applications currently in prosecution in the US.
The company is pursuing patent applications related to its formulation, composition and combinations with existing cardiovascular drugs in the US and multiple jurisdictions outside the US.
Pivotal is a specialty pharmaceutical firm focused on Omega-3 therapies for cardiovascular disease (CVD) and overall health.
Currently, VASCAZEN is available in the US as a prescription only medical food specifically formulated for the dietary management of an Omega-3 deficiency in cardiovascular patients.
It is a >90% pure Omega-3 with a proprietary 6:1 EPA:DHA fatty acid formulation, protected by a series of both US and foreign patents.